ES2051690T3 - Un complejo y su procedimiento de preparacion. - Google Patents

Un complejo y su procedimiento de preparacion.

Info

Publication number
ES2051690T3
ES2051690T3 ES86307849T ES86307849T ES2051690T3 ES 2051690 T3 ES2051690 T3 ES 2051690T3 ES 86307849 T ES86307849 T ES 86307849T ES 86307849 T ES86307849 T ES 86307849T ES 2051690 T3 ES2051690 T3 ES 2051690T3
Authority
ES
Spain
Prior art keywords
complex
preparation procedure
molecula
immunogen
pharmacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86307849T
Other languages
English (en)
Inventor
Gregory John Russell-Jones
Aizpurua Henry James De
Peter Allan Howe
Geoffery Lewis Burge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotech Australia Pty Ltd
Inhibin Pty Ltd
Original Assignee
Biotech Australia Pty Ltd
Biotechnology Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3771313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2051690(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotech Australia Pty Ltd, Biotechnology Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ES2051690T3 publication Critical patent/ES2051690T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPLEJO DE UN FARMACO, HORMONA, PEPTIDO BIOACTIVO, O INMUNOGENO CON EL SOPORTE DE LA MOLECULA DE VITAMINA B12 Y UN METODO PARA SUMINISTRAR DICHO COMPLEJO AL INTESTINO DE UN VERTEBRADO HUESPED CON EL FIN DE SUMINISTRAR EL COMPLEJO A LA CIRCULACION DEL HUESPED Y ELICITAR POR TANTO UNA RESPUESTA FARMACOLOGICA AL FARMACO, HORMONA O MOLECULA BIOACTIVA O ELICITAR UNA RESPUESTA INMUNOLOGICA SISTEMICA AL INMUNOGENO. LA INVENCION TAMBIEN PROPORCIONA UN METODO PARA LA PRODUCCION DEL COMPLEJO. ADEMAS LA INVENCION PROPORCIONA MEDICAMENTOS QUE CONTIENEN EL COMPLEJO.
ES86307849T 1985-10-10 1986-10-10 Un complejo y su procedimiento de preparacion. Expired - Lifetime ES2051690T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPH283885 1985-10-10

Publications (1)

Publication Number Publication Date
ES2051690T3 true ES2051690T3 (es) 1994-07-01

Family

ID=3771313

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86307849T Expired - Lifetime ES2051690T3 (es) 1985-10-10 1986-10-10 Un complejo y su procedimiento de preparacion.

Country Status (16)

Country Link
US (2) US5428023A (es)
EP (1) EP0220030B1 (es)
JP (1) JPH08779B2 (es)
KR (1) KR940003057B1 (es)
CN (1) CN1045391C (es)
AT (1) ATE64534T1 (es)
CA (1) CA1330791C (es)
DK (1) DK167099B1 (es)
ES (1) ES2051690T3 (es)
GR (1) GR3002160T3 (es)
HK (1) HK69094A (es)
IL (1) IL80264A (es)
IN (1) IN165029B (es)
NZ (1) NZ217821A (es)
WO (1) WO1987002251A1 (es)
ZA (1) ZA867703B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4842868A (en) * 1986-09-26 1989-06-27 Helwing Robert F Covalently bonded active agents with carbonium ion base groups
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
IL93982A0 (en) * 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
GR900100249A (el) * 1990-03-28 1992-06-30 Purdue Research Foundation Μεθοδος δια την ηυξημενην δια των μεμβρανων μεταφοραν εξωγενων μοριων.
HK1002252A1 (en) * 1991-04-02 1998-08-07 Biotech Australia Pty. Limited Oral delivery systems for microparticles
JPH08510260A (ja) * 1993-05-20 1996-10-29 バイオテック・オーストラリア・プロプライエタリー・リミテッド Ｌｈｒｈ拮抗剤
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
CA2187346C (en) * 1994-04-08 2010-06-29 A. Charles Morgan, Jr. Receptor modulating agents and methods relating thereto
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5840880A (en) * 1994-04-08 1998-11-24 Receptagen Corporation Receptor modulating agents
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
EP1015475A1 (en) * 1995-10-19 2000-07-05 Receptagen Corporation Vitamin b 12? receptor modulating agents and methods related thereto
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
ES2244006T3 (es) * 1996-08-27 2005-12-01 University Of Utah Research Foundation Bioconjugados y administracion de agentes bioactivos.
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
WO1999065529A1 (en) * 1998-06-15 1999-12-23 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy
FR2787029A1 (fr) * 1998-12-09 2000-06-16 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de vitamine b12 pour la delivrance d'agents actifs au systeme nerveux central
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
DE19930729A1 (de) * 1999-07-05 2001-01-11 Achim Goepferich Blockcopolymere zur Herstellung biomimetischer Oberflächen
JP2003531105A (ja) 1999-10-15 2003-10-21 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 造影剤および治療薬として有用なコバラミン結合体
MXPA02003771A (es) * 1999-10-15 2005-04-28 Mayo Foundation Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes anti-tumor.
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CN1441676B (zh) 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
CA2427146A1 (en) * 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US6752986B2 (en) 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
WO2003000010A2 (en) * 2001-06-20 2003-01-03 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
EP2168598A1 (en) * 2001-09-28 2010-03-31 Purdue Research Foundation Method of Treatment Using Ligand-Immunogen Conjugates
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
FR2839407B1 (fr) * 2002-05-02 2004-12-17 Canon Kk Procede et dispositif d'ajustement de la taille maximale des sequences d'information transmises dans un reseau de telecommunications
JP4801348B2 (ja) 2002-05-06 2011-10-26 エンドサイト，インコーポレイテッド ビタミンを標的とした造影剤
KR100440725B1 (ko) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
KR20040080778A (ko) 2003-03-13 2004-09-20 삼성전자주식회사 4색 구동 액정 표시 장치 및 이에 사용하는 표시판
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
EP1893038A1 (en) * 2005-05-17 2008-03-05 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
WO2007030108A1 (en) * 2005-09-07 2007-03-15 Bebaas, Inc. Vitamin b-12 compositions
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
US20130084329A1 (en) 2005-12-09 2013-04-04 Hanall Biopharma Co., Ltd. Compositions for external application, containing adenosylcobalamin for improvement of skin diseases
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20110092416A1 (en) * 2007-03-05 2011-04-21 Robert Patrick Doyle Vitamine B12 - Peptide Conjugates for Oral Delivery
CA2678646A1 (en) * 2007-03-05 2008-09-12 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
US7851342B2 (en) * 2007-03-30 2010-12-14 Intel Corporation In-situ formation of conductive filling material in through-silicon via
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
WO2009020595A2 (en) * 2007-08-03 2009-02-12 Shaklee Corporation Nutritional supplement system
US20100330161A1 (en) * 2009-06-29 2010-12-30 Syracuse University Technology Transfer And Industrial Development Office Oral delivery of tetanus toxoid
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US8614184B2 (en) 2010-09-22 2013-12-24 Ronald P. Santasiero HCG formulations for achieving weight loss
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2015126841A1 (en) 2014-02-18 2015-08-27 Plasmatech Biopharmaceuticals, Inc. Nutritional and therapeutic mucoadhesive formulations
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2017030893A1 (en) 2015-08-14 2017-02-23 Endocyte, Inc. Method of imaging with a chelating compound
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2372066A (en) * 1940-12-23 1945-03-20 Parke Davis & Co Biological product and process of obtaining same
US3042588A (en) * 1957-04-04 1962-07-03 Distillers Co Yeast Ltd Process for producing cobalaminpeptide complexes
GB963373A (en) * 1961-12-11 1964-07-08 Glaxo Group Ltd Improvements in or relating to substituted cobamides
GB1152461A (en) * 1965-06-16 1969-05-21 Ivan Rolovich New Derivatives of Cobalamins
FR5372M (es) * 1966-02-10 1967-10-16
BE774108A (fr) * 1970-10-28 1972-04-18 Boige Jean Derives de l'hydroxocobalamine, procede pour leur preparation et utilisation de ces derives en therapeutique
IT1044233B (it) * 1973-04-04 1980-03-20 Zambelletti L S P A Derivati della vitamina bi2 ad azione vitaminica di lunga durata
JPS5247012B2 (es) * 1974-11-16 1977-11-29
US3981863A (en) * 1975-02-25 1976-09-21 Micromedic Diagonistics, Inc. Cyanocobalamin derivatives
US4133951A (en) * 1975-05-08 1979-01-09 The Radiochemical Centre Limited Vitamin B-12 cobalt-57 and process
DE2546474A1 (de) * 1975-10-17 1977-04-21 Murray M D Israel Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung
FR2373285A1 (fr) * 1976-11-25 1978-07-07 Roussel Uclaf Nouveaux derives du coenzyme b 12, procede de preparation et application a titre de medicaments de ces nouveaux produits
DE2718700A1 (de) * 1977-04-27 1978-11-02 Hans A Dipl Chem Dr Thoma Verfahren zur gesamtbestimmung von hormonen und pharmaka
US4209614A (en) * 1978-05-30 1980-06-24 E. R. Squibb & Sons, Inc. Vitamin B12 derivative suitable for radiolabeling
US4377570A (en) * 1979-01-29 1983-03-22 Merck & Co., Inc. Immunologically active dipeptidyl saccharides and methods of preparation
US4360358A (en) * 1980-03-07 1982-11-23 Yash Sharma Immunoassay with solid phase having coating containing blood platelet substitute
CA1165238A (en) * 1980-03-12 1984-04-10 Demetrios P. Papahadjopoulos Activated liposomes and method
EP0067921B1 (en) * 1981-06-22 1987-11-11 Prutec Limited A method for determining bioactive substances
EP0069450B1 (en) * 1981-06-22 1985-04-10 TECHNICON INSTRUMENTS CORPORATION (a New York corporation) Labelled vitamin b12 derivatives, their preparation and use
US4454125A (en) * 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4751285A (en) * 1986-10-09 1988-06-14 Toohey John I Derivative of cobalamin containing persulfide sulfur and glutathione
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation

Also Published As

Publication number Publication date
ZA867703B (en) 1987-06-24
EP0220030A2 (en) 1987-04-29
JPS63501015A (ja) 1988-04-14
ATE64534T1 (de) 1991-07-15
DK292587D0 (da) 1987-06-09
KR870700361A (ko) 1987-12-28
IL80264A (en) 1991-11-21
HK69094A (en) 1994-07-22
EP0220030B1 (en) 1991-06-19
DK292587A (da) 1987-06-09
DK167099B1 (da) 1993-08-30
GR3002160T3 (en) 1992-12-30
KR940003057B1 (ko) 1994-04-13
JPH08779B2 (ja) 1996-01-10
CN86107590A (zh) 1987-05-20
EP0220030A3 (en) 1987-09-30
CA1330791C (en) 1994-07-19
CN1045391C (zh) 1999-10-06
IN165029B (es) 1989-08-05
US5428023A (en) 1995-06-27
NZ217821A (en) 1989-07-27
US5589463A (en) 1996-12-31
IL80264A0 (en) 1987-01-30
WO1987002251A1 (en) 1987-04-23

Similar Documents

Publication Publication Date Title
ES2051690T3 (es) Un complejo y su procedimiento de preparacion.
ES2052645T3 (es) Acidos poliinsaturados con accion vasocinetica y formulaciones farmaceuticas y cosmeticas que los contienen.
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
ES2019570A4 (es) Dispositivo para el tratamiento termico del cuello de los preformados.
ATE94390T1 (de) Orale darreichungsformen mit verzoegerter abgabe.
ES2023976B3 (es) Procedimiento para el enriquecimiento de helio.
MX9302448A (es) Derivados iminicos ciclicos, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
ES2073533T3 (es) Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon.
ES8307494A1 (es) "un procedimiento para preparar una composicion farmaceutica que proporciona un efecto anti-inflamatorio y analgesico junto con un dano gastrico minimizado".
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
ES2045363T3 (es) Utilizacion de una composicion dietetica para la inhibicion de la adhesion celular.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
ES2019595B3 (es) Empleo de glicofurol para licuacion de preparaciones medicas, para el llenado en capsulas de gelatina blanda
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
ES2018667B3 (es) Derivados del acido 4-qionolon-3-carboxilico, procedimiento para su obtencion y preparados farmaceuticos que los contienen.
ES8702438A1 (es) Un metodo para preparar un peptido
ES544664A0 (es) Procedimiento para el diagnostico in vitro del sexo
ES2081476T3 (es) Uso de acidos grasos especificos en la fabricacion de un medicamento para su suministro por iontoforesis.
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
NO863082D0 (no) Preparat for intramuskulaer injeksjon av legemidler, vitaminer eller vaksiner.
IL37729A0 (en) Cycloaliphatic difunctional nitrogen-containing sulphonic acid esters,their manufacture and their use as medicines
ES2036523T3 (es) 4-aminoarildihidropiridinlactonas, procedimiento para su obtencion y su empleo en medicamentos.
ES2101831T3 (es) Procedimiento y productos intermedios para la preparacion de perhidro-1h-pirido(1,2-a)pirazinas ansioliticas.
ES491356A0 (es) Metodo para producir preparados medicinales para el trata- miento de carcinomas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 220030

Country of ref document: ES